Prosight Management’s X4 Pharmaceuticals XFOR Stock Holding History

Prosight Management’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,927	Closed	-$571K	–	53
2021 Q2	$571K	Buy	+2,927	New	+$736K	0.36%	41

Other funds holding XFOR

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Altium Capital Management New York $42M AUM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Prosight Management's XFOR Position: Q3 2021 in Review

Prosight Management sold out of X4 Pharmaceuticals (XFOR) in Q3 2021, closing a stake of 2,927 shares — an estimated $571K sold.

Prosight Management first reported a position in XFOR in Q2 2021 and held it in 1 quarter. The position peaked at $571K in Q2 2021. 51 funds tracked by Wall St. Rank hold XFOR as of Q3 2021.

Prosight Management reported no remaining X4 Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Prosight Management sold 2,927 X4 Pharmaceuticals shares in Q3 2021, an estimated $571K.
Prosight Management first reported a position in X4 Pharmaceuticals in Q2 2021 and held it in 1 quarter.
Prosight Management's X4 Pharmaceuticals position peaked at $571K in Q2 2021.
51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2021.

Based on Prosight Management's 13F filing for Q3 2021, filed 12 Nov 2021.